The standpoint of AIDS research and therapy programs

Anticancer Research

Volumn 18, Issue 4 B, 1998, Pages 2763-2778

  Romano, Gaetano ^a   Massi, Daniela ^b   Giordano, Antonio ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

AIDS; AIDS related malignancies; Antiretroviral treatment; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CARCINOMA; CANCER INCIDENCE; CULTURAL FACTOR; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; MEDICAL ETHICS; MEDICAL RESEARCH; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-1; HUMANS; NEOPLASMS; RESEARCH;

EID: 0031866762     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. Friedman-Kien AE: Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 5: 468-471, 1981.
2. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA and Saxon A: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425-1431, 1981.
3. Centers for Disease Control: Update on acquired immunodeficiency syndrome (AIDS), United States. Morb Mortal Wkly Rep 31: 507-514, 1982.
4. Centers for Disease Control: Pneumocystis carinii pneumonia among persons with hemophilia A. Morb Morta Wkly Rep 31: 365-367, 1982.
5. Centers for Disease Control: Possible transfusion-associated acquired immune deficiency syndrome (AIDS). Morb Mortal Wkly Rep 31: 652-654, 1982.
6. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W and Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871, 1983.
7. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B et al: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503, 1984.
8. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C et al: Isolation of a new human retrovirus from West African patients with AIDS. Science 233: 343-346, 1986.
9. Global programme on AIDS. The current global situation of the HIV/AIDS pandemic. WHO: Geneva, 1995.
10. Conference summary report. VIII International Conference on AIDS/III STD World Congress, Amsterdam, Netherlands, July 19-24, 1992.
11. d'Cruz-Grote D: Prevention of HIV infection in developing countries. Lancet 348: 1071-1074, 1996.
12. Wolffers I: HIV/AIDS and the mass media. Capacity building module for journalists, broadcasters and other media representatives. WHO: Copenhagen, 1995.
13. Wolffers I: Culture, media, and HIV/AIDS in Asia. Lancet 349: 52-54, 1997.
14. Centers for Disease Control: HIV/AIDS surveillance report. 1995.
15. Rosenberg PS: Scope of the AIDS epidemic in the United States. Science 270: 1372-1375, 1995.
16. Volkov P, Lopez AM and Torres I: Plasma trade and the HIV epidemic. Lancet 349: 327-328, 1997.
17. Cohen J: The marketplace of HIV/AIDS. Science 272: 1880-1881, 1996.
18. Greene WC: The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 324: 308-317, 1991.
19. Vaishnav Y and Wong-Staal F: The biochemistry of AIDS. Annu Rev Biochem 60: 578-630, 1992.
20. Lever A, Gottlinger H, Haseltine W and Sodroski J: Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63: 4085-4087, 1989.
21. Leis J, Baltimore D, Bishop JM, Coffin J, Fleissner E, Goff SP, Oroszlan JCS, Robinson H, Skalka AM, Temin HM et al: Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol 62: 1808-1809, 1988.
22. Earl PL, Doms RW and Moss B: Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 87: 648-652, 1990.
23. Gelderblom HR, Ozel M, Hausmann EHS, Winkel T, Pauli G and Koch MA: Fine structure of human immunodeficiency virus (HIV), immunolocalization of structural proteins and virus-cell relation. Micron Microsc 19: 41-60, 1988.
24. Ozel M, Pauli G and Gelderblom HR: The organization of the envelope projections on the surface of HIV. Arch Virol 100: 255-266, 1988.
25. Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK and Zolla-Pazner S: Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol 63: 2674-2679, 1989.
26. Weiss CD, Levy JA and White JM: Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 64: 5674-5677, 1990.
27. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR and Weissman IL: Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53: 55-67, 1988.
28. Hunter E and Swanstrom R: Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 157: 187-254, 1990.
29. Helseth E, Olshevsky U, Furman C and Sodroski J: Human immunodeficiency virus type 1 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65: 2119-2123, 1991.
30. Gelderblom HR, Ozel M and Pauli G: Morphogenesis and morphology of HIV. Structure-function relations. Arch Virol 106: 1-13, 1989.
31. Papsidero LD, Sheu M and Ruscetti FW: Human immunodeficiency virus typo 1-neutralizing monoclonal antibodies which react with p17 core protein: Characterization and epitope mapping. J Virol 63: 267-272, 1989.
32. Shang FH, Huang H, Revesz K, Chen HC, Herz R and Pinter A: Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p178ag: identification of epitopes exposed at the surfaces of infected cells. J Virol 65: 4798-4804, 1991.
33. Tramont EC: The human immunodeficiency virus. Dermatol Clin 9: 397-401, 1991.
34. Goff SP: Genetics of retroviral integration. Annu Rev Genet 26: 527-544, 1992.
35. LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, Schleif WA and Emini EA: Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 66: 7414-7419, 1992.
36. Shin C-G, Taddeo B, Haseltine WA and Farnet CM: Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol 68: 1633-1642, 11994.
37. Vaishnav Y and Wong-Staal F: The biochemistry of AIDS. Annu Rev Biochem 60: 578-630, 1992.
38. Hunter E: Macromolecular interactions in the assembly of HIV and other retroviruses. Semin Virol 5: 71-83, 1994.
39. Oroszlan S and Luftig RB: Retroviral proteinases. Curr Top Microbiol Immunol 157: 153-185, 1990.
40. Feinberg MB, Jarrett RF, Aldovini A, Gallo RC and Wong-Staal F: HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 46: 807-817, 1986.
41. Sodroski JG, Goh WC, Rosen C, Dayton A, Terwilliger E and Haeltine WA: A second posttranscriptional transactivator gene required for HTLV-III replication. Nature 322: 412-417, 1986.
42. Steffy KR, Kraus G, Looney DJ and Wong-Staal F: Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2. J Virol 66: 4532-4535, 1992.
43. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh M and Skinner MA: HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J 9: 4145-4153, 1990.
44. Laspia MF, Rice AP and Mathews MB: HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59: 283-292, 1989.
45. Trono D: HIV accessory proteins: leading roles for the supporting cast. Cell 82: 189-192, 1995.
46. Ahmad N and Venkatesan S: Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 241: 1481-1485, 1988.
47. Binninger D, Ennen J, Bonn D et al: Mutational analysis of the simian immunodeficiency virus SIVmac nef gene. J Virol 65: 5237-43, 1991.
48. Niederman TMJ, Hu W and Ratner L: Simian immunodeficiency virus negative factor suppresses the level of viral mRNA in COS cells. J Virol 65: 3538-3546, 1991.
49. Niederman TMJ, Thielan BJ and Ratner L: Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc Acad Sci USA 86: 1128-1132, 1989.
50. Terwilliger E, Sodroski JG, Rosen CA and Haseltine WA: Effects of mutations within the 3 orf region of human T-cell lymphotropic virus type III on replication and cytopathogenicity. J Virol 60: 754-760, 1986.
51. Tsunetsugu-Yokota Y, Matsuda S, Maekawa M, Saito T, Takemori T and Takebe Y: Constitutive expression of the nef gene suppresses human immunodeficiency virus type 1 (HIV-1) replication in monocytic cell lines. Virology 191: 960-963, 1992.
52. Kestler HW, III, Ringler DJ, Mori K, Panicalli DL, Sehgal PK, Daniel MD and Desrosiers RC: Importance of the nef gene for maintenance of high virus loads and for the development of AIDS. Cell 65: 651-662, 1991.
53. Aiken C, Konner J, Landau NR, Lenburg ME and Trono D: Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76: 853-864, 1994.
54. Niederman TM, Garcia JV, Hastings WR, Luria S and Ratner L: Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells. J Virol 66: 6213-6219, 1992.
55. Luria S, Chambers I and Berg P: Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin 2 mRNA. Proc Natl Acad Sci USA 88: 5326-5330, 1991.
56. Skowronski J, Parks D and Mariani R: Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. EMBO J 12: 703-713, 1993.
57. Baur AS, Sawai ET, Dazin P, Fanti WJ, Cheng-Mayer C and Peterlin BM: HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1: 373-384, 1994.
58. Miller MD, Warmerdam MT, Gaston I, Greene WC and Feinberg MB: The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179: 101-113, 1994.
59. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC and Richman DD: The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 179: 115-123, 1994.
60. Schwartz O, Marechal V, Danos O and Heard JM: Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 69: 4053-4059, 1995.
61. Maldarelli F, Chen M-Y, Willey RL and Strebel K: Human immunodeficiency virus type 1 Vpu protein is an oligomeric type 1 integral membrane. J Virol 67: 5056-5061, 1993.
62. Willey RL, Maldarelli F, Martin MA and Strebel K: Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66: 7193-7200, 1992.
63. Bour S, Schubert U and Strebel K: The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implication for the mechanism of degradation. J Virol 69: 1510-1520, 1995.
64. Willey RL, Maldarelli F, Martin MA and Strebel K: Human -immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol 66: 226-234, 1992.
65. Gottlinger HG, Dorfman T, Cohen E and Haseltine WA: Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 90: 7381-7385, 1993.
66. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA and Sodroski J: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66: 6489-6495, 1992.
67. von Schwedler U, Song J, Aiken C and Trono D: vif is crucial for human immunodeficiency type 1 proviral DNA synthesis in infected cells. J Virol 67: 4945-4955, 1993.
68. Lu Y-L, Spearman P and Ratner L: Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 67: 6542-6550, 1993.
69. Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M and Emerman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91: 7311-7315, 1994.
70. Levy DN, Fernandes LS, Williams WV and Weiner DB: Induction of cell differentiation by human immunodeficiency virus I vpr. Cell 72: 541-550, 1993.
71. Ayyavoo V, Mahboubi A, Mahalingaam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR and Weiner DB: HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor KB. Nature Med 3: 1117-1123, 1997.
72. Wu X, Conway JA, Kim J and Kapples JC: Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precurson protein. J Virol 68: 6161-6169, 1994.
73. Bednarik DP and Folks TM: Mechanisms of HIV-1 latency. AIDS 6: 3-16, 1992.
74. Kim S, Byrn J, Groopman J and Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 63: 3708-3713, 1989.
75. Muesing MA, Smith DH, Cabradilla CD et al: Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (London) 313: 450-8, 1985.
76. Butera ST and Folks TM: Application of latent HIV-1 infected cellular models to therapeutic intervention AIDS Res Hum Retroviruses 8: 991-995, 1992.
77. Petersen PK, Gekker G, Chao CC, Hu SX, Edelman C, Balfour HH Jr and Verhoef J: Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-alpha-mediated mechanism. J Clin Invest 89: 574-580, 1992.
78. Davis MG, Kenney SC, Kamine J, Pagano JS and Huang ES-Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci USA 84: 8642-8646, 1987.
79. Mosca JD, Bednarik DP, Raj, Rosec CA, Sodroski JG, Haseltine WA and Pitha PM: Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature (London) 325: 67-70, 1987.
80. Siddiqui A, Gaynor R, Srinivasan A, Mapoles J and Farr RW: Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 169: 479-484, 1989.
81. Horvat RT, Wood C and Balachandran N: Trans-activation of human immunodeficiency virus promoter by human herpesvirns 6. J Virol 63: 970-973, 1989.
82. Lin J-C: The Epstein-Barr virus DNA polymerase transactivates the human immunodeficiency type 1 5 long terminal repeat. Biochem Biophys Res Commun 195: 242-249, 1993.
83. Ouinlivan EB, Holley-Guthrie E, Mar E-C, Smith MS and Kenney S: The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J Virol 64: 1817-1820, 1990.
84. Casareale D, Fiala M, Chang CM, Cone LAS and Mocarski ES: Cytomegalovirus enhances lysis of HIV-infected T lymphoblasts. Int J Cancer 44: 124-130, 1989.
85. Golden MP, Kim S, Hammer SM, Ladd EA, Schaffer PA, DeLuca N and Albrecht MA: Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 166: 494-499, 1992.
86. Lusso P, Ensoli B, Markham PD, Ablashi DV, Salahuddin SZ, Tschachier E, Wong-Staal F and Gallo RC: Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature (London) 337: 370-373, 1989.
87. + T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression. J Virol 70: 7341-346, 1996.
88. Koval V, Clark C, Vaishnav M, Spector SA and Spector DH: Human Cytomegalovirus inhibits human immunodeficiency replication in cells productively infected by both viruses. J Virol 65: 6969-6978, 1991.
89. Carrigan DR, Knox KK and Tapper MA: Suppression of human immunodeficiency virus type 1 replication by human herpesvirus-6. J Infect Dis 162: 844-851, 1990.
90. Henderson EE, Yang JY, Zhang RD and Bealer M: Altered HIV expression and EBV-induced transformation in coinfected PBLs and PBL subpopulations. Virology 182: 186-198, 1991.
91. Romano G, Guan M, Long WK and Henderson EE: Differential effects on HIV-1 gene regulation by EBV in T lymphocytic and promonocytic cells transduced to express recombinant human CR2 (CD21). Virology 237: 23-32, 1997.
92. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 312: 763-767, 1984.
93. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC et al: Selective tropism of lymphadenopathy-associated virus (LAV) for helper-inducer T-lymphocytes. Science 225: 59-62, 1984.
94. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC and Montagnier L: T-lymphocyte T4 molecule behaves as receptor for human retrovirus LAV. Nature (London) 312: 767-771, 1984.
95. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47: 333-348, 1986.
96. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 381: 661-666, 1996.
97. + cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 381: 667-673, 1996.
98. Feng Y, Broder CC, Kennedy PE and Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmemebrane G protein-coupled receptor. Science 272: 872-877, 1996.
99. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM and Berger EA: CC-CKR-5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958, 1996.
100. Choc H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C and Sodroski J: The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148, 1996.
101. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the heta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158, 1996.
102. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, Yi Y, Turner JD, Guo HH, Du JG, Lavi E, Samson M, Libert F, Liesnard C, Vassart G, Doms RW, Parmentier M and Collman RG: Role of CCR5 in infection of primary macrophages and lymphocytes by macrophagetropic strains of human immunodeficiency virus: resistance to patient-derived and prototype resulting from the delta ccr5 mutation. J Virol 71: 3219-3227, 1997.
103. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J and Gabuzda D: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (London) 385: 645-649, 1997.
104. Clapham PR and Weiss RA: Spoilt for choice of co-receptors. Nature (London) 388: 230-231, 1997.
105. Neote K, DiGregorio D, Mak JY, Horuk R and Schall TJ: Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72: 415-425, 1993.
106. Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Ann Rev Immunol 12: 593-633, 1994.
107. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiological Rev 57: 183-289, 1993.
108. Bour S, Geleziunas R and Wainberg MA: The immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiological Rev 59: 63-93, 1995.
109. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS and Golding H: Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274: 602-605, 1996.
110. Trkola A, Dragic T, Arthos J, inley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ and Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (London) 384: 184-187, 1996.
111. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C and Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (London) 384: 179-183, 1996.
112. Samson M, Labbe O, Mollereau C, Vassart G and Parmentier M: Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35: 3362-3367, 1996.
113. Raport CJ, Schweickart VL, Chantry D, Eddy RL Jr, Shows TB, Goriska R and Gray PW: New members of the chemokines receptor gene family. J Leuk Biol 59: 18-23, 1996.
114. Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, Peitsch MC and Proudfoot AE: Selectivity and antagonism of chemokine receptors. J Leuk Biol 59: 53-60, 1996.
115. Frade JMR, Llorente M, Mellado M, Alcami J, Gutierrez-Ramos JC, Zaballos A, Real G and Martinez AC: The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. J Clin Invest 100: 497-502, 1997.
116. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N and Srinivasan A: An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66: 7517-7521, 1992.
117. Shibata R, Hoggan MD, Broscius C, Englund G, Theodore TS, Buckler-White A, Arthur LO, Israel Z, Schultz A, Lane HC et al: Isolation and characterization of a syncytium-inducing, macrophage /T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimanzee cells in vitro and in vivo. J Virol 69: 4453-4462, 1995.
118. Pantaleo G, Graziosi C and Fauci AS: New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335, 1993.
119. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170, 1996.
120. Saksela K, Stevens CE, Rubinstein P and Taylor PE: HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 123: 641-648, 1995.
121. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP and Gupta PZ: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122: 573-579, 1995.
122. Perelson AS, Neumann AU, Markowitz M, Leonard JM and Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 277: 1582-1586, 1996.
123. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169: 968-974, 1994.
124. Koot M, Van't Wout AB, Kootstra NA, de Goede RE, Tersmette M and Schuitemaker H: Relation between changes in cellular load of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 173: 349-354, 1996.
125. Bozzette SA, McCutchan JA, Spector SA, Wright B and Richman DD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 168: 1374-1379, 1993.
126. + cell depletion and progression to AIDS. Ann Intern Med 118: 681-688, 1993.
127. Ho DD, Moudgil T and Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321: 1621-1625, 1989.
128. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO and Brown AJ: Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 64: 864-872, 1990.
129. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM and Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754, 1993.
130. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocyted in HIV-1 infection. Nature (London) 373: 123-126, 1995.
131. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373: 117-122, 1995.
132. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K and Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation perion of AIDS. Nature (London) 362: 359-362, 1993.
133. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 362: 355-358, 1993.
134. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J and May RM: Antigenic diversity thresholds and the development of AIDS. Science 254: 963-969, 1991.
135. Mansky LM and Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094, 1995.
136. Sodroski J, Goh WC, Rosen C, Campbell K and Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (London) 322: 470-474, 1986.
137. York-Higgins D, Cheng-Meyer C, Bauer D, Levy JA and Dina D: Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol 64: 4016-4020, 1990.
138. Stevenson M, Meier C, Mann AM, Chapman N and Wasiak A: Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4t cells: mechanism for persistance in AIDS. Cell 53: 483-496, 1988.
139. Rasheed S, Gottlieb AA and Garry RF: Cell killing by ultraviolet-inactivated human immunodeficiency virus. Virology 154: 395-400, 1986.
140. Miller MA, Garry RF, Jaynes JM and Montelaro RC: A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res Hum Retroviruses 7: 511-519, 1991.
141. Sakai K, Ma XY, Gordienko I and Volsky DJ: Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol 65: 5765-5773, 1991.
142. Gourgeon ML, Colizzi V, Dalgleish A and Montagnier L: New concepts in AIDS pathogenesis. AIDS Res Hum Retroviruses 9: 287-289, 1993.
143. Gourgeon ML and Montagner L: Apoptopsis in AIDS. Science 260: 1269-1270, 1993.
144. + T cells from human immunodeficiency virus-infected asymtomatic individuals. J Exp Med 175: 331-340, 1992.
145. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP and Miedema F: Programmed death of T cells in HIV-1 infection. Science 257: 217-219, 1992.
146. Lewis DE, Tang DS, Adu-Oppong A, Schober W and Rodgers JR: Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol 153: 412-420, 1994.
147. Terai C, Kornbluth RS, Pauza CD, Richman DD and Carson DA: Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 87: 1710-1715, 1991.
148. Banda NK, Bernier J, Kurahara K, Kurrle R, Haigwood N, Sekali RP and Finkel TH: Crosslinking CD4 by HIV gp120 primes T cells for activation-induced apoptosis. J Exp Med 176: 1099-1106, 1992.
149. Coffin JM: Superantigens and endogenous retroviruses: confluence of puzzles. Science 255: 411-413, 1992.
150. Clerici M, Sarin A, Coffman RL, Wynn TA, Blatt SP, Hendrix CW, Wolf SF, Shearer GM and Henkart PA: Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogens. Proc Natl Acad Sci USA 91: 11811-11815, 1994.
151. Meyaard L, Schuitemaker H and Miedema F: T cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 14: 161-164, 1993.
152. + antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J Clin Invest 99: 257-266, 1997.
153. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM and Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Med 1: 129-134, 1994.
154. Muro-Cacho CA, Pantaleo G and Fauci A: Analysis of apoptosis in lymph nodes of HIV-infected persons: intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with the stage of disease or viral burden. J Immunol 154: 5555-5566, 1995.
155. + patients. Am J Pathol 146: 1542-1555, 1995.
156. Gruters RA, Terpstra FG, de Jong R, van Noesel CJ, van Lier RA and Miedema F: Selective loss of T cell functions in different stages of HIV infection. Eur J Immunol 20: 1039-1044, 1990.
157. van Noesel CJ, Gruters RA, Terpstra FG, Schellekens PT, van Lier RA and Miedema F: Functional and phenotypic evidence for a selective loss of memory T cells in asymtomatic human immunodeficiency virus-infected men. J Clin Invest 86: 293-299, 1990.
158. Shearer GM and Clerici M: Early T-helper cell defect in HIV infection. AIDS 5: 245-253, 1991.
159. Miedema F, Petit AJ, Terpstra FG, Schattenkerk JK, de Wolf F, Al BJ, Roos M, Lange JM, Danner SA, Goudsmit J et al: Immunological abnormities in human immunodeficiency virus (HIV)-infected asymtomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 82: 1908-1914, 1988.
160. + cell number and clinical staging. J Clin Invest 84: 1892-1899, 1989.
161. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert n, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R and O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273: 1856-1862, 1996.
162. Smith MW, Dean M, Carrington M, Winkler C, Hut∼ley GA, Lomb DA, Goedert n, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW. and O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277: 959-965, 1996.
163. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G and Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (London) 382: 722-725, 1996.
164. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM and the Australian Long-Term Non-Progressor Study Group: Increased frequency of CCR-5Δ32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 11: 1833-1838, 1997.
165. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA and Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-expressed individuals to HIV-1 infection. Cell 86: 367-377, 1996.
166. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD and Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 2: 1240-1243, 1996.
167. Biti R, Ffrench R, Young J, Bennetts B, Stewart G and Liang T: HIV-infection in an individual homozygous for the CCR-5 deletion allele [letter]. Nature Med 3: 252-253, 1997.
168. Theodorou I, Meyer L, Magierowska M, Katlama C and Rouzioux C: HIV-1 infection in an individual homozygous for CCR5Δ32 [letter]. Lancet 349: 1219-1220, 1997.
169. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL and White GC II: HIV-1 infection in a man homozygous for CCR5Δ32 [letter]. Lancet 349: 1219, 1997.
170. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL and Sheppard HW: The role of viral phenotype and CCR5 gene defectes in HIV-1 transmission and disease progression. Nature Med 3: 338-340, 1997.
171. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, Skinhoj P, Svejgaard A, Nielsen JO and Hofmann B: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 11: 305-309, 1997.
172. Smith MW, Carrington M, Winkler C, Lomb D, Dean M, Huttley G and O'Brien SJ: CCR2 chemokine receptor and AIDS progression [letter]. Nature Med 3: 1052-1053, 1997.
173. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Paidan N, Braun JF, Kotler DP, Wolinsky SM and Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med 2: 412-417, 1996.
174. Oberlin E, Amara A, Bachelerie F, Bessia C, Vilizier J-L, Arenzana-Seisdedos F, Schwartz O, Heard J-M, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (London) 382: 833-835, 1996.
175. Winkler C, Modi W, Smith MW, Nelson GW, Wu XW, Carrington M, Dean M, Honjo T, Tashiro K et al: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 279: 389-393, 1998.
176. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, MacDonald KS, Ngugi EN and Plummer FA: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348: 1347-1351, 1996.
177. Clerici M and Shearer GM: A TH1-TH2 switch is a critical step in the etiology of HIV-1 infection. Immunol Today 14: 107-111, 1993.
178. Salk J, Bretscher PA, Salk PL, Clerici M and Shearer GM: A strategy for prophylactic vaccination against HIV. Science 260: 1270-1272, 1993.
179. Cheynier R, Langlade-Demoyen P, Marescot M-R et al: Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol 22: 2211-2217, 1992.
180. Rowland-Jones SL, Nixon DF, Aldhous MC et al: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infants. Lancet 341: 860-861, 1993.
181. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F and Oksenhendler E: Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexuals contact of HIV-infected patients. J Clin Invest 93: 1293-1297, 1994.
182. Rowland-Jones S, Sutton J, Ariyoshi K et al: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1: 59-64, 1995.
183. Levy JA: HIV pathogenesis and long-term survival. AIDS 7: 1401-1410, 1993.
184. Peters BS, Beck EJ, Coleman DG, Wadsworth MJ, McGuiness O, Harris JR and Pinching AJ: Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face Of AIDS. BMJ 302: 203-207, 1991.
185. Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D and Broder S: Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 113: 276-282, 1990.
186. Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm JW, Sondik EJ, Yarchoan R and Broder S: Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 83: 695-701, 1991.
187. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S and Yarchoan R: Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 11: 1099-1107, 1993.
188. Levine AM: AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 85: 1382-1397, 1993.
189. Schulz TF, Boshoff CH and Weiss RA: HIV infection and neoplasia. Lancet 348: 587-591, 1996.
190. Taylor JF, Smith PG, Bull D and Pike MC: Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer 26: 483-497, 1972.
191. Beral V, Peterman TA, Berkelman RL and Jaffe HCW: Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123-128, 1990.
192. Penn I: The changing pattern of posttransplant malignancies. Transplant Proc 23: 1101-1103, 1991.
193. Qunibi W, Akhtar M, Sheth K et al: Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 84: 225-232, 1988.
194. Frances C, Farge D and Boisnic S: Syndrome de Kaposi des transplantes. J Mal Vasc 16: 163-165, 1991.
195. Brunson ME, Balakrishnan K and Penn I: HLA and Kaposi's sarcoma in solid organ transplantation. Hum Immunol 29: 56-63, 1990.
196. Mann DL, Murray C, O'Donnell M et al: HLA antigen frequencies in HIV-1 related Kaposi's sarcoma. J Acquir Immune Defic Syndr (Suppl 1) 3: 51-55, 1990.
197. Jaffe HW, Choi K, Thomas PA et al: National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part I. Epidemiologic results. Ann Intern Med 99: 145-151, 1983.
198. Beral V, Bull D, Darby S et al: Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339: 623-635, 1992.
199. Haverkos HW: The search for cofactors in AIDS, including an analysis of the association of nitrite inhalant abuse and Kaposi's sarcoma. Prog Clin Biol Res 325: 93-102, 1990.
200. Biggar RJ: Cancer in acquired immunodeficiency syndrome: an epidemiological assessment. Semin Oncol 17: 251-260, 1990.
201. Lassoued K, Clauvel JP, Fegueux S et al: AIDS-associated Kaposi's sarcoma in female patients. AIDS 5: 877-880, 1991.
202. Beral V: Epidemiology of Kaposi's sarcoma. In: Cancer, HIV, and AIDS (Veral V, Jaffe HW and Weiss RA, eds). New York: Cold Spring Harbor Laboratory, 1991, pp 5-22.
203. Afrasiabi R, Mitsuyasu R and Nashanian P: Characterization of a distinct subgroup of high risk persons with Kaposi's sarcoma and good prognosis who present with normal T4 cell number and T4:T8 ratio and negative HTLV-m/LAV serologic test results. Am J Med 81: 969-973, 1986.
204. Friedman-Kien AE, Saltzman BR, Cao YZ et al: Kaposi's sarcoma in HIV-negative homosexual men. Lancet 335: 168-169, 1990.
205. Garcia Muret MP, Pujol RM, Puig I et al: Disseminated Kaposi's sarcoma not associated with HIV infection in a bisexual man. J Am Acad Dermatol 23: 1035-1038, 1990.
206. Chang Y, Cesarman E, Pessin MS et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869, 1994.
207. Boshoff CH, Whitby D, Hatziioannou T et al: Kaposi's sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345: 1043-1044, 1995.
208. Moore P and Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 332: 1181-1185, 1995.
209. Lebbe C, de Cremoux P, Rybojad M et al: Kaposi's sarcoma and new herpesvirus [letter]. Lancet 345: 1180, 1995.
210. Moore PS, Kingsley LA, Holmberg SD et al: KSHV infection prior to onset of Kaposi's sarcoma. AIDS 10: 175-180, 1996.
211. Schalling M, Ekman M, Kaaya E et al: A role for a new herpesvirus (Kaposi's sarcoma associated herpesvirus) in different forms of KS. Nature Med 1: 707-708, 1995.
212. Ambroziak JA, Blackbourn DJ, Herndier BG et al: Herpesvirus-like sequences in HIV-infected and uninfectcd Kaposi's sarcoma patients. Science 268: 582-583, 1995.
213. Collandre H, Ferris S, Grau O et al: Kaposi's sarcoma and new herpesvirus [letter]. Lancet 345: 1043, 1995.
214. Vogel J, Hinrichs SH, Reynolds RK et al: The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature (London) 335: 606-611, 1988.
215. Ensoli B, Gendelman R, Markham P et al: Synergy between basic fibroblast growth and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature (London) 371: 674-680, 1994.
216. Ensoli B, Barillari G, Salahuddin SZ et al: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (London) 345: 84-86, 1990.
217. Roth WK, Brandstetter H and Sturzl M: Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 6: 895-913, 1992.
218. Herndier BG, Kaplan LD and McGrath MS: Pathogenesis of AIDS lymphomas. AIDS 8: 1025-1049, 1994.
219. Lyter D, Besley D, Thackeray R et al: Incidence of malignancies in the Multicenter AIDS Cohort Study (MACS). Proc ASCO 13: 50, 1994.
220. Ross R, Dworsky R, Paganini-Hill A et al: Non-Hodgkin's lymphomas in never married men in Los Angeles. Br J Cancer 52: 785-787, 1985.
221. Roithmann S, Tourani JM and Andrieu JM: AIDS-associated non-Hodgkin lymphoma. Lancet 338: 884-885, 1991.
222. Beral V, Peterman T, Berkelman R et al: AIDS associated non-Hodgkin lymphoma. Lancet 337: 805-809, 1991.
223. Vermund SH, Kelley KF, Klein RS et al. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 165: 392-400, 1991.
224. Reid R, Greenberg M, Jenson AB et al: Sexually transmitted papillomaviral infections. I. The anatomic distribution and pathologic grade of neoplastic lesions associated with different viral types. Am J Obstet Gynecol 156: 212-222, 1987.
225. Pfister H: Relationship of papillomaviruses to anogenital cancer. Obstet Gynecol Clin North Am 14: 349-361, 1987.
226. Breese PL, Judson FN, Penley KA et al: Anal human papillomavirus infection among homosexual and bisexual men: prevalence of type-specific infection and association with human immunodeficiency virus. Sex Transm Dis 22: 7-14, 1995.
227. Maggwa BN, Hunter DJ, Mhugna S et al: The relationship between HIV infection and cervical intraepithelial neoplasia among women attending two family planning clinics in Nairobi, Kenia. AIDS 7: 733-738, 1993.